Lyra Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: LYRA · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Lyra Therapeutics, DEF 14A, Annual Meeting, Proxy Statement, Virtual Meeting
TL;DR
<b>Lyra Therapeutics, Inc. is holding its virtual Annual Meeting of Stockholders on June 13, 2024, and urges shareholders to vote.</b>
AI Summary
Lyra Therapeutics, Inc. (LYRA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Lyra Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 13, 2024, at 8:00 a.m. Eastern time. The meeting will be conducted as a completely virtual meeting via live webcast. Stockholders are urged to vote their shares promptly by phone, internet, or mail. Instructions for attending the virtual meeting and voting are provided in the proxy materials. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 29, 2024.
Why It Matters
For investors and stakeholders tracking Lyra Therapeutics, Inc., this filing contains several important signals. This DEF 14A filing provides essential information for stockholders to participate in the company's governance and decision-making processes. The virtual format aims to increase accessibility for stockholders to attend and vote at the Annual Meeting.
Risk Assessment
Risk Level: low — Lyra Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement, providing information about an upcoming shareholder meeting and does not contain new financial or operational data that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy materials to understand the proposals being voted on and to cast their votes for the Annual Meeting.
Key Numbers
- June 13, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders.)
- 8:00 a.m. Eastern time — Annual Meeting Time (2024 Annual Meeting of Stockholders.)
- DEF 14A — Filing Type (Definitive Proxy Statement.)
- 001-39273 — SEC File Number (Lyra Therapeutics, Inc. SEC File Number.)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
- Maria Palasis, Ph.D. (person) — Signed the letter to stockholders.
- June 13, 2024 (date) — Date of the Annual Meeting of Stockholders.
- April 29, 2024 (date) — Date of the Notice & Proxy Statement.
FAQ
When did Lyra Therapeutics, Inc. file this DEF 14A?
Lyra Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Lyra Therapeutics, Inc. (LYRA).
Where can I read the original DEF 14A filing from Lyra Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Lyra Therapeutics, Inc..
What are the key takeaways from Lyra Therapeutics, Inc.'s DEF 14A?
Lyra Therapeutics, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: Lyra Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 13, 2024, at 8:00 a.m. Eastern time.. The meeting will be conducted as a completely virtual meeting via live webcast.. Stockholders are urged to vote their shares promptly by phone, internet, or mail..
Is Lyra Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Lyra Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement, providing information about an upcoming shareholder meeting and does not contain new financial or operational data that would indicate significant risk.
What should investors do after reading Lyra Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the proposals being voted on and to cast their votes for the Annual Meeting. The overall sentiment from this filing is neutral.
How does Lyra Therapeutics, Inc. compare to its industry peers?
Lyra Therapeutics, Inc. operates in the medical instruments and apparatus sector, focusing on surgical and medical devices.
Are there regulatory concerns for Lyra Therapeutics, Inc.?
The filing is made under Rule 14a-101 of the Securities Exchange Act of 1934, governing proxy statements.
Industry Context
Lyra Therapeutics, Inc. operates in the medical instruments and apparatus sector, focusing on surgical and medical devices.
Regulatory Implications
The filing is made under Rule 14a-101 of the Securities Exchange Act of 1934, governing proxy statements.
What Investors Should Do
- Review the proxy statement for details on proposals and director nominations.
- Vote your shares by the deadline to ensure your voice is heard.
- Attend the virtual annual meeting on June 13, 2024, to participate in discussions.
Key Dates
- 2024-06-13: Annual Meeting of Stockholders — Key date for stockholder participation and voting.
- 2024-04-29: Filing Date of DEF 14A — Indicates when the proxy materials were made public.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 Annual Meeting, providing information on upcoming proposals and meeting logistics.
Filing Stats: 4,884 words · 20 min read · ~16 pages · Grade level 11.3 · Accepted 2024-04-29 16:33:50
Key Financial Figures
- $0.001 — f record of shares of our common stock, $0.001 par value per share, as of the close of
Filing Documents
- d774329ddef14a.htm (DEF 14A) — 348KB
- g774329g09y01.jpg (GRAPHIC) — 11KB
- g774329g09y02.jpg (GRAPHIC) — 2KB
- g774329page001.jpg (GRAPHIC) — 75KB
- g774329page002.jpg (GRAPHIC) — 77KB
- 0001193125-24-122508.txt ( ) — 577KB
Security Ownership of Certain Beneficial Owners and
Security Ownership of Certain Beneficial Owners and Management 32 Certain Relationships and Related Person Transactions 35 Stockholders Proposals 37 Other Matters 38 Delinquent Section 16(a) Reports 37 Solicitation of Proxies 38 Lyras Annual Report on Form 10-K 39 Table of Contents LYRA THERAPEUTICS, INC. 480 Arsenal Way Watertown, Massachusetts 02472 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD THURSDAY, JUNE 13, 2024 The Annual Meeting of Stockholders (the Annual Meeting) of Lyra Therapeutics, Inc., a Delaware corporation (the Company), will be held at 8:00 a.m. Eastern time on Thursday, June 13, 2024. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/LYRA2024 and entering your 16-digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or on the instructions that accompanied your proxy materials. The Annual Meeting will be held for the following purposes: To elect Konstantin Poukalov and Nancy L. Snyderman, M.D., FACS as Class I Directors to serve until the Companys 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified; To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024; To approve an amendment to our Restated Certificate of Incorporation to provide for the exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (DGCL); and To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting. Holders of record of our common stock as of the close o